2.57  -0.11 (-4.1%)		02-15 16:00
Open: 2.62 High: 2.64 Volume: 201,271		Pre. Close: 2.68 Low: 2.56 Market Cap: 53(M)

Short term
Mid term
Targets	6-month :	3.21	1-year :	3.35
Resists	First :	2.75	Second :	2.86
Pivot price	2.61
Supports	First :	2.55	Second :	2.12
MAs	MA(5) :	2.56	MA(20) :	2.63
	MA(100) :	2.46	MA(250) :	3.57
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	3.5	D(3) :	3.4
RSI	RSI(14): 41
52-week	High :	6.51	Low :	1.46

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EAR ] has closed above bottom band by 22.2%. Bollinger Bands are 59.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.57 - 2.58	2.58 - 2.6
Low:	2.54 - 2.55	2.55 - 2.57
Close:	2.55 - 2.57	2.57 - 2.59

Eargo, Inc., a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States. The company markets and sells hearing aids. It sells its products direct-to-consumer and through omni-channel. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was incorporated in 2010 and is headquartered in San Jose, California.

Thu, 23 Jan 2025
Hearing Aid Market Expected to Experience Positive Growth till 2031 - Demant AS, Cochlear Ltd, Eargo Inc. - openPR.com

Sun, 29 Oct 2023
Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. for $13 million. - MarketScreener

Tue, 15 Aug 2023
Eargo Hearing Aids Review (2024) | Cost, Features & More - Everyday Health

Tue, 17 Jan 2023
Eargo Effects 1-for-20 Reverse Stock Split - Yahoo Finance

Mon, 27 Jun 2022
Eargo Strengthens Financial Position with up to $125 Million Strategic Investment from Patient Square Capital - GlobeNewswire

Fri, 20 May 2022
Hearing Aid Company Agrees to $34 Million Settlement Over False Claims Act Allegations - CCO

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	21 (M)
Held by Insiders	1.964e+007 (%)
Held by Institutions	5.4 (%)
Shares Short	12 (K)
Shares Short P.Month	0 (K)

EPS	-8.755e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-263.2 %
Operating Margin	-206.5 %
Return on Assets (ttm)	-60.1 %
Return on Equity (ttm)	-2 %
Qtrly Rev. Growth	4.111e+007 %
Gross Profit (p.s.)	3.1
Sales Per Share	308.83
EBITDA (p.s.)	0
Qtrly Earnings Growth	15 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-75 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	1.75

Dividend	0
Forward Dividend	42080
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.